The healthcare sector has performed well this year, and Eli Lilly (NYSE: LLY), the largest company in the industry by market cap, has helped lift the average. We can't say the same for Intuitive Surgical (NASDAQ: ISRG), a medical device specialist that has lagged broader equities year to date. However, even though they have moved in different directions this year, both of these healthcare stocks are worth buying for investors focused on the long game. Here's why Eli Lilly and Intuitive Surgical could perform well over the long run. Image source: The Motley Fool. In the third quarter, Eli Lilly's revenue increased by 39% year over year to $24.4 billion. That's very impressive top-line growth for a pharmaceutical giant. In fact, Eli Lilly has been growing its revenue much faster than its similarly sized peers in the pharmaceutical industry for the better part of the last three years.
CryptoAlerta — análise de criptomoedas e mercado em tempo real